AIM ImmunoTech Overview
Compare AIM ImmunoTech's DCF valuation ($-0.29) to today's market price.
Get informed when a big investor buys or sells
+ Follow$-0.29
Overvalued by 262.7% based on the discounted cash flow analysis.
AIM ImmunoTech's discounted cash flow stands at $-0.29. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Discounted cash flow values AIM by forecasting cash the business could generate and bringing those cash flows to present value. Stockcircle's latest estimate is $-0.29, implying the shares look overvalued by about 262.7%. Pair DCF with P/E, growth, and balance-sheet metrics before making a decision.
The history chart shows how AIM ImmunoTech's DCF fair value evolved across reporting periods, while the comparison chart places AIM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, DCF fair value is commonly used to spot outliers. AIM ImmunoTech's reading of $-0.29 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
